Shihong Sheng Sign in to save

OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

Patent citations

–

Works (all)

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (8)

1× Clinical Biostatistics, Janssen Research and Development, Spring House, PA, USA
1× Janssen Research & Development Spring House Pennsylvania
1× Janssen Research & Development Spring House Pennsylvania
1× Clinical Biostatistics, Janssen Research & Development LLC, Spring House, PA, USA
1× Janssen Research & Development, LLC Spring House Pennsylvania
1× Janssen Research & Development, LLC Spring House Pennsylvania
1× . Janssen Research & Development , Raritan ( NJ) , USA
1× .Janssen Research & Development, Raritan (NJ), USA

Papers 5 stored

All · Aachen affiliation only

Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III , Randomized, Double‐Blind , Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis
2021 Arthritis & Rheumatology article Medicine Spondyloarthritis Studies and Treatments Open access cited by 1 patent

104

citations
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies
2021 The Lancet Rheumatology article Medicine Spondyloarthritis Studies and Treatments

103

citations
EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19 SUBUNIT OF IL-23, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-52 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
2021 Congresso Brasileiro de Reumatologia conference-paper Medicine Spondyloarthritis Studies and Treatments Open access

2

citations
Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis
2020 Arthritis & Rheumatology article Medicine Spondyloarthritis Studies and Treatments Open access

80

citations
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
2020 The Lancet article Medicine Spondyloarthritis Studies and Treatments Open access cited by 2 patents

359

citations

5 results

Shihong Sheng ▲ Sign in to save

Departments & institutes in Aachen

Papers 5 stored

Shihong Sheng Sign in to save